Ilumya Administration: Forms, Strengths, Methods, and Additional Details
Ilumya (tildrakizumab-asmn), a prescription drug, is a solution in a prefilled, single-dose syringe and is injected subcutaneously by a healthcare professional. This medication is used to treat moderate to severe plaque psoriasis in certain adults who are candidates for systemic treatment or phototherapy [1][4].
The typical dosing schedule for Ilumya is designed for long-term treatment and is based on Phase 3 clinical studies for chronic plaque psoriasis. The initial dose is administered at Week 0, followed by a second dose at Week 4. After this induction phase, maintenance doses are given every 12 weeks thereafter [1][4].
Each dose consists of 100 mg of Ilumya, injected subcutaneously, usually in the stomach, thigh, or upper arm [1][4]. This regimen optimizes the drug’s efficacy and safety profile, with a 12-week interval between maintenance doses [1][4].
Missed appointments for Ilumya injections should be rescheduled as soon as possible to maintain the treatment schedule. Using a medication reminder can help ensure that you don't miss a dose. It's not recommended to get maintenance Ilumya injections more often than once every 12 weeks [1][4].
It's important to note that the dosing schedule for Ilumya in the treatment of psoriatic arthritis may differ, as Ilumya is currently only FDA-approved for plaque psoriasis, not psoriatic arthritis [1][2][5]. For more specific information about Ilumya, consult your doctor or refer to additional resources.
[1] FDA-approved prescribing information for Ilumya
[2] European Medicines Agency summary of product characteristics for Ilumya
[3] American Academy of Dermatology: Ilumya treatment guidelines
[4] National Psoriasis Foundation: Ilumya treatment information
[5] ClinicalTrials.gov: Ilumya for psoriatic arthritis
- Dermatology professionals should be aware that Ilumya, a medical-condition treatment for psoriasis, is a prescription drug primarily used in certain adults for moderate to severe plaque psoriasis who require systemic treatment or phototherapy.
- The pharmacy-dispensed Ilumya, a solution in a prefilled syringe, is administered by healthcare professionals through subcutaneous injections, and a single dose contains 100 mg of the drug.
- Skin care for those undergoing Ilumya therapies and treatments may require maintenance doses every 12 weeks, optimizing the drug's efficacy and safety profile.
- Seek advice from your doctor if you have any questions about the health-and-wellness guidelines for using Ilumya, as the dosing schedule might differ based on the specific medical-condition being treated, such as psoriatic arthritis.
- Skin-care therapies and treatments with Ilumya involve reasonable considerations, including keeping a schedule for injections to maintain the long-term treatment, following the FDA-approved prescribing information, and possibly utilizing a medication reminder.
